Table 3 Pharmacodynamic (PD) and pharmacokinetic (PK) properties of the ICSs available for the management of asthma in Canada[53, 54]
ICS | Oral bioavailability (%) | Lung deposition (%) | Particle size (μm) | Protein-binding (% not bound) | Half-life (h) | Systemic clearance (L/h) |
|---|---|---|---|---|---|---|
Beclomethasone dipropionate | 20/40* | 50-60 | <2.0 | 13 | 2.7* | 150/120* |
Budesonide | 11 | 15-30 | >2.5 | 12 | 2.0 | 84 |
Ciclesonide | <1/<1* | 50 | <2.0 | 1/1* | 0.5/4.8* | 152/228* |
Fluticasone propionate | ≤1 | 20 | 2.8 | 10 | 14.4 | 66 |